SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF
THE
SECURITIES EXCHANGE ACT OF 1934
Date
of
Report (Date of earliest event reported) July 10, 2007 (July 5,
2007)
CHEMBIO
DIAGNOSTIC, INC.
(Exact
name of registrant as specified in its charter)
|
Nevada
|
0-30379
|
88-0425691
|
||
|
(State
or other jurisdiction
|
(Commission
File Number)
|
(IRS
Employer
|
||
|
of
Incorporation)
|
Identification
Number)
|
|||
|
3661
Horseblock Road
|
||||
|
Medford,
NY 11763
|
||||
|
(Address
of principal executive offices)
|
||||
|
631-924-1135
|
||||
|
(Registrant’s
Telephone Number)
|
N/A
(Former
name or former address, if changed since last report)
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
o Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
o Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
ITEM
7.01. Regulation FD Disclosure.
|
|
On
July 5, 2007, the Company issued a press release titled “Chembio
to Present at 2007 C.E. Unterberg Towbin Emerging Growth Opportunities
Conference.” The press release is attached hereto as Exhibit
99.1.
|
|
|
On
July 10, 2007, the Company issued a press release titled “CORRECTING
AND REPLACING Chembio to Present at 2007 C.E. Unterberg Towbin
Emerging
Growth Opportunities Conference.” The press release is
attached hereto as Exhibit
99.2.
|
|
|
On
July 11, 2007, certain officers of the Company intend
to deliver an investor presentation that will include the
slides attached hereto as Exhibit 99.3 to this Current Report on
Form 8-K. The Company undertakes no obligation to update,
supplement or amend the materials attached as Exhibit
99.3.
|
ITEM
9.01. Financial Statements and Exhibits
(d) Exhibits.
|
99.1
|
Press
Release titled “Chembio to Present at 2007 C.E.
Unterberg Towbin Emerging Growth Opportunities Conference” issued July
5, 2007.
|
|
99.2
|
Press
Release titled “CORRECTING AND REPLACING Chembio to
Present at 2007 C.E. Unterberg Towbin Emerging Growth Opportunities
Conference” issued July 10,
2007.
|
|
99.3
|
PDF
of Chembio Presentation to be delivered
on July 11, 2007.
|
In
accordance with General Instruction B.2 of Form 8-K, the information in this
Current Report on Form 8-K shall not be deemed “filed” for the purpose of
Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed
incorporated by reference in any filing. This Current Report on Form
8-K does not constitute a determination of whether any information included
herein is material.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.
Date: July
10,
2007
Chembio Diagnostics, Inc.
By: /s/
Lawrence A. Siebert
Lawrence
A. Siebert
Chief
Executive Officer
Chembio to Present at 2007 C.E. Unterberg Towbin
Emerging
Growth Opportunities Conference
MEDFORD,
N.Y. - July 5, 2007 - Chembio Diagnostics Inc.’s (OTCBB: CEMI) Chief Executive
Officer, Lawrence Siebert, will present at the 2007 C.E. Unterberg Towbin
Emerging Growth Opportunities Conference on Thursday, July 12th at 3:00PM
(EDT)
at New York City’s Mandarin Oriental Hotel. A live webcast of the presentation
will be available on the Company’s website at
www.chembio.com. Additional information regarding the
conference can be found at www.unterberg.com.
Mr.
Siebert will speak about the market opportunities for the Company’s HIV and
other rapid diagnostic tests including the FDA approved products being marketed
by Inverness Medical Innovations, Inc. as well as Chembio’s newly patented Dual
Path Platform (DPP™), for which the Company is generating a significant amount
of interest.
ABOUT
CHEMBIO
Chembio
Diagnostics, Inc., a developer and manufacturer of rapid diagnostic tests
for
infectious diseases, is on the frontlines of the global battle against the
AIDS
pandemic. The Company has received marketing approval from the FDA for its
SURE
CHECK® HIV 1/2 and HIV 1/2 STAT-PAK® rapid tests, marketed in the United States
by Inverness Medical Innovations. The Company also manufactures rapid tests
for
veterinary Tuberculosis and Chagas Disease. In March 2007 Chembio was
issued a United States patent for the Dual Path Platform (DPP(TM)), a next
generation lateral flow platform. DPP has demonstrated significant advantages
over currently available lateral flow methods, including increased sensitivity,
sample flexibility, and multiplexing capabilities.
For
further information please visit www.chembio.com.
FORWARD-LOOKING
STATEMENTS
Statements
contained herein that are not historical facts may be forward-looking statements
within the meaning of the Securities Act of 1933, as amended. Forward-looking
statements include statements regarding the intent, belief or current
expectations of the Company and its management. Such statements are
estimates only, as the Company has not completed the preparation of its
financial statements for those periods, nor has its auditor completed the
audit
of those results. Actual revenue may differ materially from those anticipated
in
this press release. Such statements reflect management's current views, are
based on certain assumptions and involve risks and uncertainties. Actual
results, events, or performance may differ materially from the above
forward-looking statements due to a number of important factors, and will
be
dependent upon a variety of factors, including, but not limited to, Chembio's
ability to obtain additional financing, to obtain regulatory approvals in
a
timely manner, and the demand for Chembio's products. Chembio undertakes
no
obligation to publicly update these forward-looking statements to reflect
events
or circumstances that occur after the date hereof or to reflect any change
in
Chembio's expectations with regard to these forward-looking statements or
the
occurrence of unanticipated events. Factors that may impact Chembio's success
are more fully disclosed in Chembio's most recent public filings with the
U.S.
Securities and Exchange Commission.
Contact:
Matty
Arce - 631-924-1135 ext 123.
CORRECTING
AND REPLACING Chembio to Present at 2007 C.E. Unterberg Towbin Emerging Growth
Opportunities Conference
MEDFORD,
NY – July 10, 2007 - First paragraph, first sentence, the presentation date and
time should read Wednesday, July 11th at 2:30pm (EDT) sted: (Thursday, July
12th
at 3:00PM (EDT)).
The
corrected release reads:
Chembio
to Present at 2007 C.E. Unterberg Towbin Emerging Growth Opportunities
Conference
Chembio
Diagnostics Inc.’s (OTCBB: CEMI) Chief Executive Officer, Lawrence Siebert, will
present at the 2007 C.E. Unterberg Towbin Emerging Growth Opportunities
Conference on Wednesday, July 11th at 2:30pm (EDT) at New York City’s Mandarin
Oriental Hotel. A live webcast of the presentation will be available on the
Company’s website at www.chembio.com. Additional information
regarding the conference can be found at www.unterberg.com.
Mr.
Siebert will speak about the market opportunities for the Company’s HIV and
other rapid diagnostic tests including the FDA approved products being marketed
by Inverness Medical Innovations, Inc. as well as Chembio’s newly patented Dual
Path Platform (DPP™), for which the Company is generating a significant amount
of interest.
ABOUT
CHEMBIO
Chembio
Diagnostics, Inc., a developer and manufacturer of rapid diagnostic tests
for
infectious diseases, is on the frontlines of the global battle against the
AIDS
pandemic. The Company has received marketing approval from the FDA for its
SURE
CHECK® HIV 1/2 and HIV 1/2 STAT-PAK® rapid tests, marketed in the United States
by Inverness Medical Innovations. The Company also manufactures rapid tests
for
veterinary Tuberculosis and Chagas Disease. In March 2007 Chembio was
issued a United States patent for the Dual Path Platform (DPP(TM)), a next
generation lateral flow platform. DPP has demonstrated significant advantages
over currently available lateral flow methods, including increased sensitivity,
sample flexibility, and multiplexing capabilities.
For
further information please visit www.chembio.com.
FORWARD-LOOKING
STATEMENTS
Statements
contained herein that are not historical facts may be forward-looking statements
within the meaning of the Securities Act of 1933, as amended. Forward-looking
statements include statements regarding the intent, belief or current
expectations of the Company and its management. Such statements are
estimates only, as the Company has not completed the preparation of its
financial statements for those periods, nor has its auditor completed the
audit
of those results. Actual revenue may differ materially from those anticipated
in
this press release. Such statements reflect management's current views, are
based on certain assumptions and involve risks and uncertainties. Actual
results, events, or performance may differ materially from the above
forward-looking statements due to a number of important factors, and will
be
dependent upon a variety of factors, including, but not limited to, Chembio's
ability to obtain additional financing, to obtain regulatory approvals in
a
timely manner, and the demand for Chembio's products. Chembio undertakes
no
obligation to publicly update these forward-looking statements to reflect
events
or circumstances that occur after the date hereof or to reflect any change
in
Chembio's expectations with regard to these forward-looking statements or
the
occurrence of unanticipated events. Factors that may impact Chembio's success
are more fully disclosed in Chembio's most recent public filings with the
U.S.
Securities and Exchange Commission.
Contact:
Matty
Arce - 631-924-1135 ext 123.
EXHIBIT 99.3 - Chembio Investor Presentation: SEE PDF FILE